Jonas Helma

6PUBLICATIONS
26CO-AUTHORS
Molecular targetsNeural engineeringComposite and hybrid materialsGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 20, 2025
TUB-010, a Novel Anti-CD30 Antibody-Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy.

Marcus Gerlach, Saskia Schmitt, Philipp Cyprys

|Jul 16, 2025
TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile.

Annette M Vogl, Saskia Schmitt, Isabelle Mai

|Oct 13, 2023
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.

Saskia Schmitt, Paul Machui, Isabelle Mai

|Oct 30, 2019
N-Hydroxysuccinimide-Modified Ethynylphosphonamidates Enable the Synthesis of Configurationally Defined Protein Conjugates.

Marc-André Kasper, Marcus Gerlach, Anselm F L Schneider

|Sep 16, 2017
Nanobodies: Chemical Functionalization Strategies and Intracellular Applications.

Dominik Schumacher, Jonas Helma, Anselm F L Schneider

|Mar 23, 2016
Current Status: Site-Specific Antibody Drug Conjugates.

Dominik Schumacher, Christian P R Hackenberger, Heinrich Leonhardt

Pageof 1

Frequent Collaborators

5 joint publications

Dominik Schumacher

4 joint publications

Marc-André Kasper

3 joint publications

Annette M Vogl

3 joint publications

Marcus Gerlach